Russian Heart Failure Journal 2014year Acute pulmonary heart disease in extremely severe chronic obstructive pulmonary disease. Possibility for using ivabradine


To access this material please log in or register

Register Authorize
2014/№4

Acute pulmonary heart disease in extremely severe chronic obstructive pulmonary disease. Possibility for using ivabradine

Akhmetzyanova E. Kh., Kuchukova G. U., Gaynitdinova V. V., Kvezereli N. I., Bogoroditskaya O. A., Latyshev Yu. M., Orlova D. I., Gareeva G. I.

Keywords: ivabradine, pulmonary heart disease, chronic obstructive pulmonary disease, heart rate


DOI: 10.18087/rhfj.2014.4.1992

The article presents a clinical experience with the ivabradine treatment in acute pulmonary heart disease and cardiogenic shock. A patient with extremely severe COPD, panlobular bullous pulmonary emphysema, and chronic decompensated pulmonary heart disease associated with polysegmental pneumonia was diagnosed with disruption of bullae, bilateral pneumothorax, acute pulmonary heart disease, and grade III shock. The patient was put on inotropic support for 17 days. The inotropic drug treatment at increasing doses was associated with stable, persistent tachycardia reaching 120 bpm and reduced EF from 62–72 % to 40 % associated with repeated disruption of bullae. The ivabradine administration reduced the heart rate to 85 bpm; a tendency to stabilization of the patient’s condition began to show; and EF recovered. Death of the patient was caused by lung bleeding due to vascular erosions of large bullae.
  1. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33 (14):1787–1847.
  2. Машковский, М. Д. Лекарственные средства: пособие для врачей. –16‑е изд., пеpеpаб., испр. и доп. – М.: Новая Волна, 2011. –1216 с
  3. Fasullo S, Cannizzaro S, Maringhini G et al. Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings. J Card Fail. 2009 Dec;15 (10):856–63.
  4. Сайганов С. А., Гришкин Ю. Н. Использование селективного ингибитора If-каналов ивабрадина для лечения синусовой тахикардии при острой сердечной недостаточности у больных ишемической болезнью сердца с нижним инфарктом миокарда. Кардиоваскулярная терапия и профилактика. 2010;9 (3):52–56.
  5. Heusch G, Skyschally A, Gres P et al. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J. 2008 Sep;29 (18):2265–75.
  6. Fox K, Borer JS, Camm AJ et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007 Aug 28;50 (9):823–30.
Akhmetzyanova E. Kh., Kuchukova G. U., Gaynitdinova V. V. et al. Acute pulmonary heart disease in extremely severe chronic obstructive pulmonary disease. Possibility for using ivabradine. Russian Heart Failure Journal. 2014;85 (4):261–265

To access this material please log in or register

Register Authorize
Ru En